Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

36

Revenue 2017

Xtandi

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Xtandi was produced by Astellas.

Astellas extends phase III programme for Rydapt rival gilteritinib

Astellas extends phase III programme for Rydapt rival gilteritinib Gilteritinib is one of a clutch of new drugs Astellas is banking on to inject renewed growth into its revenues as prostate cancer blockbuster Xtandi (enzalutamide) starts to slow down, and

Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A

Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A Pfizer is struggling to grow sales of its new cancer drug Xtandi, the main asset in its takeover of Medivation last September. ... The US's largest drugmaker booked $141m from Xtandi (enzalutamide) in the second quarter, up from $131m in the first

Pfizer hits accelerator on Xtandi trial in early prostate cancer

Pfizer hits accelerator on Xtandi trial in early prostate cancer failure. Both studies have been billed as having the potential to drive uptake of J&J's drug, adding pressure on Xtandi. ... And Pfizer and Astellas' position was further weakened by another trial called PLATO, which showed that adding Xtandi to Zytiga

Practice-changing data for J&J's Zytiga in prostate cancer

Practice-changing data for J&J's Zytiga in prostate cancer Astellas' fast-growing Xtandi (enzalutamide) which already has a pre-chemotherapy indication.

Astellas agrees €800m deal to buy Belgian biotech Ogeda

Astellas agrees €800m deal to buy Belgian biotech Ogeda prostate cancer therapy Xtandi (enzalutamide).

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics